Climb Bio (CLYM) FDA Approvals

Climb Bio logo
$9.21 -0.07 (-0.78%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Upcoming FDA Events for Climb Bio

Climb Bio (CLYM) has upcoming FDA regulatory milestones for CLYM116. The table below outlines estimated target dates and event types for these pending regulatory actions.

DrugTarget DateAnnouncement
CLYM116H1 2027Initial Data
Climb Bio, Inc. announced that the NAVIGATE-2 Phase 2 trial enrolling, with initial data expected in the first half of 2027 (October 23, 2026)

Climb Bio's Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Climb Bio (CLYM). Over the past two years, Climb Bio has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Budoprutug and CLYM116. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

Budoprutug FDA Regulatory Timeline and Events

Budoprutug is a drug developed by Climb Bio for the following indication: Treatment of Primary Membranous Nephropathy. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

CLYM116 FDA Regulatory Timeline and Events

CLYM116 is a drug developed by Climb Bio for the following indication: for IgAN. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Climb Bio FDA Events - Frequently Asked Questions

In the past two years, Climb Bio (CLYM) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Climb Bio (CLYM) has reported FDA regulatory activity for the following drugs: CLYM116 and Budoprutug.

The most recent FDA-related event for Climb Bio occurred on October 24, 2026, involving Budoprutug. The update was categorized as "Clinical Data," with the company reporting: "Climb Bio, Inc. announced new clinical data for budoprutug, its anti-CD19 monoclonal antibody (mAb), in two immune-mediated renal diseases, primary membranous nephropathy (pMN) and minimal change disease (MCD)."

Current therapies from Climb Bio in review with the FDA target conditions such as:

  • for IgAN - CLYM116
  • Treatment of Primary Membranous Nephropathy - Budoprutug
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:CLYM last updated on 10/26/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners